Pharmacological and genetic inhibition of RORγ strongly block prostate cancer (PCa) and TNBC cell growth and metastasis, suggesting that RORγ is a novel therapeutic target for cancer (Wang et al., 2016; Cai et al., 2019; Wang et al., 2020; Zheng et al., 2020; Zhang et al., 2021; Zou et al., 2022b). This evidence concerns the gene RORC and prostate carcinoma.